Bukwang authorized to resell Levovir, KFDA says

Published: 2009-05-15 07:00:00
Updated: 2009-05-15 07:00:00
The Korea Food and Drug Administration has allowed Bukwang Pharm to remarket Levovir, saying the benefits of the product outweigh the risks.

Levovir is an antiviral agent for treatment of hepatitis caused by the hepatitis B virus based on DNA polymerase inhibition.

The drug agency said in i...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.